Literature DB >> 2996431

Structural requirements for the biological activity of thymopentin analogs.

G A Heavner, T Audhya, D Kroon, G Goldstein.   

Abstract

Thymopentin, the synthetic pentapeptide Arg-Lys-Asp-Val-Tyr, corresponds to residues 32-36 of the thymic hormone thymopoietin. Thymopentin, like thymopoietin, induces intracellular cGMP elevations in the human T-cell line, CEM. Thymopentin also displaces radiolabeled thymopoietin from a receptor glycoprotein prepared from CEM cells, provided that a nonapeptide corresponding to thymopoietin is added to block thymopoietin binding to an additional binding site. Twenty nine analogs with single position substitutions were synthesized by solid-phase or classical solution synthesis, and are evaluated in these assays. All analogs that were active gave positive effects in both assays. A number of substitutions were tolerated at positions 2, 4, and 5, but there was an absolute requirement for L- or D-Arg at position 1 and L- or D-Asp at position 3 to maintain biological activity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2996431     DOI: 10.1016/0003-9861(85)90499-0

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  4 in total

1.  Nasal epithelial permeation of thymotrinan (TP3) versus thymocartin (TP4): competitive metabolism and self-enhancement.

Authors:  M C Schmidt; W Rubas; H P Merkle
Journal:  Pharm Res       Date:  2000-02       Impact factor: 4.200

Review 2.  Immunomodulation with thymopentin: in vitro studies.

Authors:  J Duchateau; K Bolla
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

Review 3.  Thymopentin and splenopentin as immunomodulators. Current status.

Authors:  V K Singh; S Biswas; K B Mathur; W Haq; S K Garg; S S Agarwal
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

4.  Molecular analysis of thymopentin binding to HLA-DR molecules.

Authors:  Zuojia Liu; Xiliang Zheng; Jin Wang; Erkang Wang
Journal:  PLoS One       Date:  2007-12-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.